The FDA last week granted an accelerated approval to Seagen’s Tukysa in combination with Herceptin as a second-line therapy for RAS wild-type, HER2-positive unresectable or metastatic colorectal cancer. The combination is the first FDA-approved therapy in HER2-positive metastatic colorectal cancer. Tukysa was first approved in 2020, also in combination with Herceptin, for the treatment of advanced unresectable or metastatic HER2-positive breast cancer. For this indication, the drug currently holds covered or better status for virtually all (99%) of insured lives in the U.S. under the pharmacy benefit. About 8% of covered lives have preferred access to Tukysa, growing to 25% with utilization management restrictions applied.
SOURCE: MMIT Analytics, as of 1/23/23